The study, sponsored by Fondazione Policlinico Universitario Agostino Gemelli IRCCS, aims to explore novel therapeutic strategies targeting zDHHC enzymes to address synaptic and cognitive deficits in Alzheimer's Disease (AD). Given the increasing prevalence of AD and the limited efficacy of current treatments, this research could position itself in a lucrative market with significant unmet needs. The absence of existing drugs targeting zDHHCs presents a unique opportunity for first-mover advantage. However, the competitive landscape includes established players in AD therapeutics, necessitating thorough diligence on potential partnerships or licensing opportunities to enhance development and commercialization prospects.